Benign prostatic enlargement with persistent nocturia due to idiopathic nocturnal polyuria — MSRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Start desmopressin oral lyophilisate 50 micrograms at bedtime, advise overnight fluid restriction, and check serum sodium in the first week and at 1 month
Explanation lettering: C = shown as A · E = shown as B · B = shown as C · A = shown as D · D = shown as E
This is persistent nocturia caused by confirmed nocturnal polyuria rather than residual bladder outlet obstruction: his voiding symptoms and residual volume have improved on tamsulosin, while the frequency-volume chart shows excessive nocturnal urine production. Relevant secondary causes have been excluded and conservative measures have failed. NICE supports oral desmopressin in this setting. For a man, the licensed Noqdirna dose is 50 micrograms sublingually 1 hour before bedtime. Fluid intake should be minimised from 1 hour before until 8 hours after dosing. In people aged 65 years or over, sodium must be normal before treatment and rechecked in the first week and at 1 month because of hyponatraemia risk. A is inappropriate because increasing alpha-blockade does not address nocturnal polyuria and may increase adverse effects. B would be reasonable for persistent urgency/frequency due to overactive bladder, but the chart identifies excess nocturnal urine production. C is a NICE-considered alternative for nocturnal polyuria, but desmopressin is appropriate here after conservative measures where contraindications are absent. E is not indicated for uncomplicated LUTS without haematuria, recurrent infection, suspected malignancy or other evidence of urinary tract abnormality.
Reference: NICE CG97: Lower urinary tract symptoms in men: management — Recommendations (Last updated June 2015; last reviewed December 2024) — https://www.nice.org.uk/guidance/cg97/chapter/recommendations Noqdirna 50 micrograms oral lyophilisate — Summary of Product Characteristics (2026) — https://www.medicines.org.uk/emc/product/4372/smpc